Evidence for First-Line Advanced Therapy (MONALEESA-2): As a Phase III trial, it evaluated the efficacy and safety of ribociclib combined with letrozole as a first-line regimen in postmenopausal patients with HR-positive, HER2-negative advanced breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.